Results 171 to 180 of about 54,156 (279)

Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia　― A Post-Marketing Survey (J-POSSIBLE) ―

, 2023
Arihiro Kiyosue, Satoshi Yasuda, Akiyoshi Tomura, Makiko Usami, Hidenori Arai   +4 more
openalex   +2 more sources

Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors- Are We Doing Better? A Systematic Review on Treatment Disparity [PDF]

, 2020
Chetana Singh, Danel J Valero, Javariya Nisar, J. I. Ramirez, Karisma K Kothari, Sasank Isola, Aleyda M San Hernandez, Domonick K Gordon   +7 more
openalex   +1 more source

Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]

J Transl Med
Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Pistritto C, Tiralongo M, Di Stefano C, Pennisi G, De Francesco EM, Malaguarnera R, Di Pino A, Piro S, Scicali R.   +13 more
europepmc   +1 more source

Mendelian randomization analysis of lipid-lowering drug targets and neuropsychiatric disorders. [PDF]

Medicine (Baltimore)
Peng S, Liu M, Du F, Li K.
europepmc   +1 more source

Table_1_Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis.DOCX

, 2021
Jiahui Liu (724342), Fangfang Fan (312738), Xingyu Luo (3684229), Wenjun Ji (822811), Yaokun Liu (11743949), Yan Zhang (8098), Bo Zheng (170888)   +6 more
openalex   +2 more sources

Dramatic Coronary Artery Aneurysm Regression After Coronary Artery Bypass Grafting and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. [PDF]

Interdiscip Cardiovasc Thorac Surg
Yokoyama Y, Higashino H, Fujieda H, Abe M.   +3 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Induces Platelet-Derived Transforming Growth Factor-<i>β</i> to Promote Myocardial Fibrosis After Myocardial Infarction. [PDF]

Hum Mutat
Wang Q, Huang W, Xia D, Wang F, Nair S.
europepmc   +1 more source

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study [PDF]

, 2017
Joshua Choi, Amir Khan, Michael Jarmin, Naila Goldenberg, Charles J. Glueck, Ping Wang   +5 more
openalex   +1 more source

Advances in Beyond Statin Lipid Therapies for ASCVD Risk Reduction. [PDF]

J Atheroscler Thromb
Shimabukuro M.
europepmc   +1 more source

Subtilisin Novo. The Three-Dimensional Structure and Its Comparison with Subtilisin BPN' [PDF]

European Journal of Biochemistry, 1972
J, Drenth, W G, Hol, J N, Jansonius, R, Koekoek   +3 more
openaire   +2 more sources